Azeliragon (TTP488) - 98%, high purity , Advanced glycosylation end product-specific receptor antagonist, CAS No.603148-36-3, Advanced glycosylation end product-specific receptor antagonist

Item Number
A413440
Grouped product items
SKUSizeAvailabilityPrice Qty
A413440-5mg
5mg
In stock
$58.90
A413440-10mg
10mg
In stock
$98.90
A413440-25mg
25mg
In stock
$222.90
A413440-50mg
50mg
In stock
$315.90

Basic Description

Synonyms3-(4-(2-Butyl-1-(4-(4-chlorophenoxy)phenyl)-1H-imidazol-4-yl)phenoxy)-N,N-diethylpropan-1-amine | 3-(4-{2-Butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl}phenoxy)-N,N-diethylpropan-1-amine | Azeliragon free base | BCP16862 | UNII-LPU25F15UQ | D11147
Specifications & PurityMoligand™, ≥98%
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeANTAGONIST
Mechanism of actionAdvanced glycosylation end product-specific receptor antagonist
Product Description

Information

Azeliragon (TTP488, PF-04494700) is an orally bioavailable small molecule that inhibits thereceptor for advanced glycation endproducts (RAGE), which is an immunoglobulin-like cell surface receptor overexpressed in brain tissues of patients with AD.

Product Properties

ALogP8.3

Associated Targets(Human)

AGER Tchem Advanced glycosylation end product-specific receptor (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
SLC6A4 Tclin Serotonin transporter (12625 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KCNH2 Tclin HERG (29587 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP1A2 Tchem Cytochrome P450 1A2 (26471 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP2C9 Tchem Cytochrome P450 2C9 (32119 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP2C19 Tchem Cytochrome P450 2C19 (29246 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP3A4 Tclin Cytochrome P450 3A4 (53859 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SH-SY5Y (11521 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HepG2 (196354 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AGER Tchem Advanced glycosylation end product-specific receptor (291 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SUM149PT (97 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Hdac6 Histone deacetylase 6 (222 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rep Replicase polyprotein 1ab (378 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SARS-CoV-2 (38078 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Names and Identifiers

IUPAC Name 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]imidazol-4-yl]phenoxy]-N,N-diethylpropan-1-amine
INCHI InChI=1S/C32H38ClN3O2/c1-4-7-9-32-34-31(25-10-16-28(17-11-25)37-23-8-22-35(5-2)6-3)24-36(32)27-14-20-30(21-15-27)38-29-18-12-26(33)13-19-29/h10-21,24H,4-9,22-23H2,1-3H3
InChi Key KJNNWYBAOPXVJY-UHFFFAOYSA-N
Canonical SMILES CCCCC1=NC(=CN1C2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)C4=CC=C(C=C4)OCCCN(CC)CC
Isomeric SMILES CCCCC1=NC(=CN1C2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)C4=CC=C(C=C4)OCCCN(CC)CC
PubChem CID 11180124
Molecular Weight 532.12

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

4 results found

Lot NumberCertificate TypeDateItem
H2206412Certificate of AnalysisJun 13, 2022 A413440
H2206419Certificate of AnalysisJun 13, 2022 A413440
H2206434Certificate of AnalysisJun 13, 2022 A413440
H2206438Certificate of AnalysisJun 13, 2022 A413440

Related Documents

References

1. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J et al..  (2003)  RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain..  Nat Med,  (7): (907-13).  [PMID:12808450]
2. Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AM.  (2014)  Effect of TTP488 in patients with mild to moderate Alzheimer's disease..  BMC Neurol,  14  (3): (12).  [PMID:24423155]
3. Saito S, Ihara M.  (2014)  New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy..  Front Aging Neurosci,  (3): (290).  [PMID:25368578]

Solution Calculators